Patheon Selected By Grünenthal
News Apr 28, 2016
Patheon has announced that it has signed a strategic agreement with Grünenthal to serve as its preferred development partner for its products made using Grünenthal’s innovative abuse deterrent formulation technology INTAC®. Patheon was selected to assist with the development of advanced INTAC® based products including single-entity and fixed-dose combination solid oral dosage forms with immediate and modified release properties.
INTAC® is Grünenthal’s proprietary technology designed to reduce the potential for abuse of controlled substances. As part of the agreement, Grünenthal has agreed to install specialized equipment in Patheon’s Cincinnati manufacturing site. Through their partnership, Grünenthal and Patheon will partner to offer new solutions to the broader pharmaceutical industry. This concept of locating equipment in a Patheon facility – “condo model” – allows clients to benefit from Patheon’s process, people and infrastructure to simplify manufacturing.
“This agreement is a tangible example of the deeper, collaborative relationships we are pursuing and winning with clients,” said Mike Lehmann, executive vice president, global sales and marketing. “Over the past several years we have built a business to meet the needs of a breadth of clients – from emerging pharma companies to large multinationals.
This collaboration brings together Grünenthal’s innovative approach to research and development and the specialized technical manufacturing capabilities of Patheon to bring novel therapies to the marketplace for the patients who need them.
“It is recognized in the healthcare industry that,” said Dr. Klaus-Dieter Langner, Chief Scientific Officer Grünenthal Group, “prescription drug abuse is an issue of growing concern in the United States. Typically it is opioids, CNS depressants and stimulants that are the three most established drug classes that are abused. Novel formulation technologies will help reduce that abuse potential.”